Work

Analysis of AR-driven resistance mechanisms in a phase 1/2 study of EPI-506, a novel AR N-terminal domain inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC) with progression after enzalutamide or abiraterone.

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.15_suppl.tps5030

Authors: Kim N. Chi, Ulka N. Vaishampayan, Michael S. Gordon, David C. Smith, Emmanuel S. Antonarakis, Ryan Vance Dittamore, Chan Chandhasin, Frank Perabo, Robert B. Montgomery

Institutions: BC Cancer Agency, The Barbara Ann Karmanos Cancer Institute, HonorHealth, Pinnacle Oncology Hematology, University of Michigan, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Epic Sciences (United States), Essa Pharma (United States), University of Washington

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2891504038

Cites:

Cited by:

Related to: 10